Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $95 and keeps an Overweight rating on the shares. Mirum’s proposed acquisition of Bluejay Therapeutics for $250M in cash, $300M in stock, and $200M in tiered milestone payments is a “steal,” the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
-
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
-
Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MIRM:
Disclaimer & DisclosureReport an Issue
-
Mirum Pharmaceuticals Announces Merger with Bluejay Therapeutics
-
Mirum Pharmaceuticals to acquire Bluejay Therapeutics in cash, stock transaction
-
Mirum Pharmaceuticals enrolls first patient in Phase 2 BLOOM study of MRM-3379
-
Mirum Pharmaceuticals: Strategic Positioning and Strong Defense Justify Buy Rating
Content Original Link:
" target="_blank">
